Silverman Joshua — SEC insider filings
SEC reporting owner CIK 1524858. 59 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers the 50 most recent of 59 filings on record, filed 2021-04-09 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 7 legs across 3 filings — 125,000 shares, $266,834 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 7 legs across 6 filings — 109,884 shares, $260,060 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 57.
- Largest priced transaction: sale of 39,008 shares @ $5.17 ($201,687) in Fabric.AI, Inc., filed 2021-06-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Fabric.AI, Inc. (FABC) | Chief Executive Officer, Director | 10 | — | 6 legs · 90,872 sh · $237,779 | 10 |
| TAO Synergies Inc. (TAOX) | Executive Chairman, Director | 14 | 1 leg · 10,000 sh · $83,000 | 1 leg · 19,012 sh · $22,280 | 16 |
| Q/C TECHNOLOGIES, INC. (QCLS) | Executive Chairman, Director | 9 | 3 legs · 15,000 sh · $103,358 | — | 13 |
| PharmaCyte Biotech, Inc. (PMCB) | CEO and President, Director | 3 | 3 legs · 100,000 sh · $80,476 | — | 3 |
| Petros Pharmaceuticals, Inc. (PTPI) | Director | 10 | — | — | 12 |
| FEMASYS INC (FEMY) | Director | 4 | — | — | 3 |
Insider filings — Silverman Joshua
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | TAO Synergies Inc. (TAOX) | Grant/award (A): 131,250 @ $0 · Grant/award (A): 131,250 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 4 | Fabric.AI, Inc. (FABC) | Tax withholding (F): 44,820 @ $2.28 | EDGAR |
| 2026-10-02 | 4 | Q/C TECHNOLOGIES, INC. (QCLS) | Grant/award (A): 16,620 @ $0 · Grant/award (A): 77,390 @ $0 | EDGAR |
| 2026-10-02 | 4/A | Q/C TECHNOLOGIES, INC. (QCLS) | Grant/award (A): 16,806 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Fabric.AI, Inc. (FABC) | Grant/award (A): 358,565 @ $0 · Tax withholding (F): 44,820 @ $3.70 · Tax withholding (F): 44,820 @ $3.69 | EDGAR |
| 2026-06-05 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Grant/award (A): 4,375,000 @ $0 | EDGAR |
| 2026-05-19 | 4 | TAO Synergies Inc. (TAOX) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-04-15 | 4 | Q/C TECHNOLOGIES, INC. (QCLS) | Grant/award (A): 162,162 @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | FEMASYS INC (FEMY) | Holdings only — no transactions reported | EDGAR |
| 2026-01-07 | 4 | PharmaCyte Biotech, Inc. (PMCB) | Purchase (P): 30,000 @ $0.78 · Purchase (P): 30,000 @ $0.79 · Purchase (P): 40,000 @ $0.83 | EDGAR |
| 2026-01-02 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Grant/award (A): 4,375,000 @ $0 | EDGAR |
| 2025-12-12 | 4 | PharmaCyte Biotech, Inc. (PMCB) | Grant/award (A): 575,000 @ $0 · Tax withholding (F): 258,750 @ $1.02 | EDGAR |
| 2025-11-14 | 4 | Q/C TECHNOLOGIES, INC. (QCLS) | Grant/award (A): 91,356 @ $0 | EDGAR |
| 2025-10-31 | 4 | StableX Technologies, Inc. (SBLX) | Grant/award (A): 220,513 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | TAO Synergies Inc. (TAOX) | Grant/award (A): 100,000 @ $0 · Tax withholding (F): 40,000 @ $7.23 · Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-10-06 | 4 | Q/C TECHNOLOGIES, INC. (QCLS) | Grant/award (A): 8,644 @ $0 | EDGAR |
| 2025-07-02 | 4 | TAO Synergies Inc. (TAOX) | Grant/award (A): 41,919 @ $0 · Tax withholding (F): 16,768 @ $7.85 | EDGAR |
| 2025-06-27 | 4 | FEMASYS INC (FEMY) | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Grant/award (A): 1,000,000 @ $0 | EDGAR |
| 2024-12-02 | 4 | AYRO, Inc. (AYRO) | Disposition to issuer (D): 6,166 @ $0 · Grant/award (A): 146,052 @ $0 · Option exercise (M): 97,368 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | FEMASYS INC (FEMY) | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2024-04-10 | 4 | Synaptogenix, Inc. (SNPX) | Grant/award (A): 800 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | PharmaCyte Biotech, Inc. (PMCB) | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | FEMASYS INC (FEMY) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-08-03 | 4 | AYRO, Inc. (AYRO) | Sale (S): 12,740 @ $0.82 | EDGAR |
| 2023-06-09 | 4 | MyMD Pharmaceuticals, Inc. (MYMD) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-05-05 | 4 | AYRO, Inc. (AYRO) | Sale (S): 11,927 @ $0.49 | EDGAR |
| 2023-04-28 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Option exercise (M): 6,722 · Option exercise (M): 6,722 (derivative) @ $0 | EDGAR |
| 2023-04-12 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Grant/award (A): 39,000 (derivative) @ $0 | EDGAR |
| 2023-03-31 | 4 | Synaptogenix, Inc. (SNPX) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-02-03 | 4 | AYRO, Inc. (AYRO) | Sale (S): 7,171 @ $0.71 · Grant/award (A): 197,333 @ $0 | EDGAR |
| 2023-01-25 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Option exercise (M): 2,515 · Option exercise (M): 2,515 (derivative) @ $0 | EDGAR |
| 2022-12-20 | 4 | Synaptogenix, Inc. (SNPX) | Sale (S): 19,012 @ $1.17 | EDGAR |
| 2022-12-01 | 4/A | Synaptogenix, Inc. (SNPX) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-12-01 | 4/A | Synaptogenix, Inc. (SNPX) | Grant/award (A): 42,250 @ $0 | EDGAR |
| 2022-11-17 | 4 | Synaptogenix, Inc. (SNPX) | Grant/award (A): 144,000 (derivative) @ $0 | EDGAR |
| 2022-11-03 | 4 | AYRO, Inc. (AYRO) | Sale (S): 12,855 @ $0.82 · Sale (S): 7,171 @ $0.59 | EDGAR |
| 2022-06-23 | 4/A | Synaptogenix, Inc. (SNPX) | Other (J): 0 (derivative) | EDGAR |
| 2022-04-11 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Grant/award (A): 67,227 (derivative) @ $0 | EDGAR |
| 2022-04-06 | 4 | Synaptogenix, Inc. (SNPX) | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2022-02-03 | 4 | AYRO, Inc. (AYRO) | Grant/award (A): 114,729 @ $0 | EDGAR |
| 2022-01-07 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Grant/award (A): 25,156 (derivative) @ $0 | EDGAR |
| 2021-11-29 | 4 | MyMD Pharmaceuticals, Inc. (MYMD) | Purchase (P): 6,734 @ $6.30 · Purchase (P): 3,266 @ $7.09 · Purchase (P): 5,000 @ $7.55 | EDGAR |
| 2021-10-15 | 4 | MyMD Pharmaceuticals, Inc. (MYMD) | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2021-07-15 | 4 | Synaptogenix, Inc. (SNPX) | Grant/award (A): 90,000 @ $0 | EDGAR |
| 2021-06-16 | 4 | Synaptogenix, Inc. (SNPX) | Purchase (P): 10,000 @ $8.30 | EDGAR |
| 2021-06-08 | 4 | AYRO, Inc. (AYRO) | Sale (S): 39,008 @ $5.17 | EDGAR |
| 2021-04-20 | 4 | MyMD Pharmaceuticals, Inc. (MYMD) | Option exercise (M): 109,500 · Tax withholding (F): 38,325 @ $4.94 · Option exercise (M): 109,500 (derivative) @ $0 | EDGAR |
| 2021-04-09 | 4 | Petros Pharmaceuticals, Inc. (PTPI) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1524858 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs